Functional cytotoxicity and infiltration capacity are critical benchmarks for testing immunotherapies in vitro.

Careful assessment of immunomodulatory effects of new drugs in combination with already approved ones is crucial before these treatment regimens can be considered in the clinical setting. Due to unlimited possibilities of new combinations, especially in the view of synergy effect observed with double checkpoint inhibition blockade. cpo has developed a unique screening platform for immunoncology.  Our automated and high throughput (384 well plate) platform allows for efficient and cost effective testing of these combinations in regards to the tumor – immune system interplay

If you want to test your cellular therapies, small molecules, bi-specific antibodies, immune checkpoint inhibitors, ADCs, vaccines and combinations of thereof please contact our experts